GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures

Abstract Background Atogepant, the first oral CGRP receptor antagonist approved for migraine prevention, has demonstrated efficacy and safety in randomized clinical trials (RCT). However, prospective real-world data are lacking. Objective To explore the effectiveness, safety, and tolerability of ato...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Piero Barbanti, Gabriella Egeo, Francesca Pistoia, Cinzia Aurilia, Paola Scatena, Steno Rinalduzzi, Silvia Strumia, Antonio Salerno, Fabio Frediani, Andrea Galli, Massimo Autunno, Laura Di Clemente, Maurizio Zucco, Maria Albanese, Francesco Bono, Pietrantonio Bruno, Laura Borrello, Stefano Messina, Alberto Doretti, Angelo Ranieri, Cecilia Camarda, Rosario Vecchio, Valeria Drago, Giulia Fiorentini, Carlo Tomino, Stefano Bonassi, Paola Torelli, Alice Mannocci, for the Italian Migraine Registry (I-GRAINE) study group
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-05-01
Edice:	The Journal of Headache and Pain
Témata:	Atogepant Migraine CGRP Treatment Real-world Disability
On-line přístup:	https://doi.org/10.1186/s10194-025-02068-2
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!